Results

Total Results: 1,134 records

Showing results for "days".

261. Binge-Eating Research-Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/binge-eating_research-protocol.pdf
     July 21, 2014 - The binge eating occurs, on average, a. at least 2 days a week for 6 months (DSM-IV frequency and duration … Final health outcomes o Behavioral - Binge eating: frequency of binge episodes, frequency of binge days … male or female) - Reproductive function o Social and occupational functioning - Work or school days … Dyslipidemia · GERD, irritable bowel syndrome Social and occupational functioning · Lost work or school days … treatment harms, and costs (e.g., health care cost and use, lost work days).

262. Juvenile-Arthritis-Dmards Surveillance (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/juvenile-arthritis-dmards_surveillance.pdf
     March 14, 2013 - In period A, 2.6 days /month and 2.3 parents; usual activity days/month were gained. … In period B there were 1.9 vs 0.9 {P=0.033} and 0.2 vs -1.3 {P=0.109} school days/ month and parents … ’ usual activity days/month respectively, in abatacept vs placebo Author, year Trial n Subjects … Normalized body temperature and absence of evanescent rashes were achieved after a median of 4 days … Time between start of etanercept and IBD was 9 days to 4.5 years Author, year Trial n Subjects

263. Juvenile-Arthritis-Dmards Surveillance (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/juvenile-arthritis-dmards_surveillance.pdf
     March 14, 2013 - In period A, 2.6 days /month and 2.3 parents; usual activity days/month were gained. … In period B there were 1.9 vs 0.9 {P=0.033} and 0.2 vs -1.3 {P=0.109} school days/ month and parents … ’ usual activity days/month respectively, in abatacept vs placebo Author, year Trial n Subjects … Normalized body temperature and absence of evanescent rashes were achieved after a median of 4 days … Time between start of etanercept and IBD was 9 days to 4.5 years Author, year Trial n Subjects

264. Making Healthcare Safer IV_Rapid Review: Use of Structured Handoff Protocols for Intrahospital Within-Unit Transitions (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/structured-handoff-rapid-research.pdf
     January 01, 2025 - : Intervention: 60.4 Control: 60.4 Total adverse events per 1,000 hospital days: Intervention: … Mostly or entirely academic 3,106 patient admissions Medical error rate per 1,000 patient days … ICU LOS Intervention: 7.3 days Control: 7.5 days Duration of mechanical ventilation Intervention … : 3.5 days Control: 4.3 days Reintubations within 24 hours Intervention: 1.2% Control: 1.5% … stay: Mean difference between intervention and control: 5.26, p=0.20 Reuptake rate within 30 days

265. Agenda: Impact of Healthcare Algorithms on Racial and Ethnic Disparities (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/healthcare-algorithms-agenda-for-March-23.pdf
     May 29, 2025 - Agenda: Impact of Healthcare Algorithms on Racial and Ethnic Disparities 1 IMPACT OF HEALTHCARE ALGORITHMS ON RACIAL AND ETHNIC DISPARITIES IN HEALTH AND HEALTHCARE AGENDA March 2–3, 2023 National Institutes of Health (NIH) Natcher Conference Center 45 Center Drive, Building 45, Bethesda, MD 20892 …

266. Noninvasive Treatments for Low Back Pain (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/back-pain-treatment_research_executive.pdf
     February 01, 2016 - back pain problem that has persisted at least 3 months and has resulted in pain on at least half the days … Opioids vs. acetaminophen, acute LBP: Days to return to work, pain Insufficient One trial found no … acetaminophen in days to return to work; pain was not reported. Long acting opioids vs. … (RR, 0.82; 95% CI, 0.72 to 0.94) and at 10–14 days (RR, 0.71; 95% CI, 0.54 to 0.93) vs. placebo, and … lower likelihood of no overall improvement at 10–14 days (RR, 0.63; 95% CI, 0.42 to 0.97).

267. Antibiotics-Respiratory-Infection Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/antibiotics-respiratory-infection_executive.pdf
     January 01, 2016 - Evidence on the impact on hospitalizations is less clear: five studies reported none within 30 days … statistically significant, the absolute differences were small (1.1% vs. 0.2% hospitalization at 30 days … ; 5 vs. 6 days symptom duration). … risk of hospital admissions (2 RCTs) No difference in reconsultation, diagnostic testing use, or days … in overall antibiotic prescribing, hospitalizations, duration of symptoms, reconsultations, 16 days

268. Phenylketonuria Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/phenylketonuria_executive.pdf
     February 01, 2012 - 1 Comparative Effectiveness Review Number 56 Adjuvant Treatment for Phenylketonuria (PKU) Executive Summary Background Etiology Phenylketonuria (PKU) is a metabolic disorder in which an inability to properly metabolize the amino acid phenylalanine (Phe) leads to a buildup of Phe in the blood, causing neurot…

269. Evidence Summary_Comparative Effectiveness Review No. 250_Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2022 Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-evidence-summary-2022-update_0.pdf
     January 01, 2022 - Evidence Summary_Comparative Effectiveness Review No. 250_Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2022 Update Comparative Effectiveness Review Number 250 Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2022 Update Evide…

270. S81 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s81.pdf
     October 01, 2007 - for a bleeding or anticoagulation problem, an ADE was predicted if either length of stay (LOS) was �4 days … and there was a complication; or if LOS was �4 days and the patient was a woman with cardiac dysrhythmias … Using 4 nodes, the HOCTA model predicted drug-induced delirium if LOS was �3 days and the patient was … older than 75 years or had diabetes mellitus; or if LOS was �5 days.

271. Protocol Amendment - Safety of Vaccines 030413 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/vaccines-safety-protocol-130325.pdf
     September 18, 2012 - 2011 immunization schedule recommended for U.S. adults18* are safe in the short term (within 30–42 days … following immunization) or long term (>42 days after immunization)? … recommended for U.S. children and adolescents in 201119* are safe in the short term (within 30–42 days … following immunization) or long term (>42 days after immunization)?

272. Comparative Effectiveness of Coronary Bypass Surgery and Percutaneous Coronary Interventions for Multivessel Disease: A Pooled Analysis of Individual Patient Data from Ten Randomized Trials (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cad-pci-bypass_addendum.pdf
     February 01, 2010 - Most patients receive the assigned treatment within 60 days of randomization. … Within 90 days of randomization, 75 (2%) of 3889 patients assigned to CABG died, compared with 74 ( … The composite endpoint of death or myocardial infarction within 90 days, which could be assessed in … Data on stroke within 90 days of randomization were available from seven trials:1,5-10 26 (1%) of 2268

273. Management of Uterine Fibroids - Evidence Summary (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/evidence-summary-cer-195-uterine-fibroids-final.pdf
     December 01, 2017 - Likewise, bleeding characteristics, such as days of bleeding and severity of bleeding as measured by … Studies consistently reported significant improvement in measures of quality of life symptoms (days … Assessment duration (where clearly reported) in comparative studies ranged from 15 days to 24 months … Time to return to usual activity after hysterectomy averaged 30 to 40 days in three studies. … One study reported faster recovery (mean 22 days) after laparoscopic hysterectomy.

274. Disposition of Comments for Migraine in Adults: Preventive Pharmacologic Treatments (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/migraine-prevention_disposition-comments.pdf
     April 18, 2013 - Three estimates used migraine that occurred ≥15 days per month, with prevalence ranging from 0 to 0.7% … Prevalence and Prevention guideline recommends preventive treatment for those with two or more headache days … with disability or four or more days with or without disability.30 this was a paper based on the … decreased the likelihood of acute drug use in patients with a baseline of more than 12 monthly migraine days … Reviewer 3 Report: Topiramate was also better than placebo in reducing monthly migraine days by ≥50

275. Methods Research Report: Developing Consistent and Useful Quality Improvement Study Data Extraction (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/developing-consistent-useful-quality-improvement.pdf
     September 01, 2020 - Duration of intervention should specify total hours/days of intervention. … Asthma symptom days, period of frequent symptoms, persistent asthma, asthma-specific functional status … Clinical measures: emergency department visits, did not missing school days due to wheezing or asthma … (out-patient and hospital visits for asthma care), functional limitations (school or pre- school days … bronchial responsiveness, air flow meter variability, symptom frequency, knowledge of asthma, days

276. Heart-Failure-Natriuretic-Peptide Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/heart-failure-natriuretic-peptide_executive.pdf
     November 01, 2013 - Generally, studies predicting short-term mortality (up to 31 days) and longer term mortality (24 months … showed that patients in the BNP/NT-proBNP group had more days of survival outside the hospital than … All-cause mortality and composite outcomes across different time intervals (from 14 days to 7 years … Time intervals were heterogeneous for studies of both decompensated HF (from 31 days to 6.8 years) and … • Inclusion of all relevant endpoints: cardiovascular mortality, total mortality, days alive and not

277. Crohns-Disease Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/crohns-disease_executive.pdf
     February 01, 2014 - Inflammatory Bowel Disease Questionnaire [IBDQ], Short Inflammatory Bowel Disease Questionnaire), and days … other measure of perianal disease) • Patient-reported outcomes (health-related quality of life, IBDQ, days … • Last reported time point KQ4 • Patient-reported outcomes (health-related quality of life, IBDQ, days … ) or persistently (within 90 days and greater than 365 days) than with no TNF-alpha inhibitors or no … ) or persistently (within 90 days and greater than 365 days) than with no thiopurines.

278. Effective Health Care (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0320_06-17-2009.pdf
     January 01, 2009 - Effective Health Care Topic Number: 0175 Document Completion Date: 3-24-10 1 Results of Topic Selection Process & Next Steps  Serum free light chain assay analysis for the diagnosis, management, and prognosis of plasma cell dyscrasias will go forward for refinement as a systematic review. T…

279. S50 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s50.pdf
     October 01, 2007 - nutritional interventions (use of oral medical nutritional supplements or tube feeding for more than 21 days … reuptake inhibitor (SSRI) and new antipsychotic medications, use of disposable briefs for more than 14 days

280. CER 229 Evidence Summary: Opioid Treatments for Chronic Pain (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/cer-229-opioid-treatments-chronic-pain-evidence-summary.pdf
     April 01, 2020 - diagnosis found buprenorphine taper associated with a lower percentage of negative urine samples, more days